17 Patients were randomly assigned to receive either 1 injection of the adjuvanted RSV vaccine or placebo. Of 24,966 study participants in 17 countries, 12,467 individuals received 1 dose of the adjuvanted RSV vaccine, and 12,499 individuals were given the placebo. Vaccine efficacy against RSV-...
the safety and reactogenicity profile of the coadministered regimen was similar to the childhood vaccines given alone. Beyfortus should not be mixed with any vaccine in the same syringe or vial. When administered concomitantly with injectable vaccines, they should be given with separate syringes and...
The maternal vaccine is modelled to be given seasonally from November to March to a proportion of pregnant people in the third trimester (25- to 45-year-old women). The infant strategies were compared to the current base strategy (0). RSV vaccination of older adults The vaccine in older ...
vaccines have significant downsides.Moreover, as the engineered bRSV F glycoprotein is structurally and reactively similar to the prefusion-stabilized human RSV (hRSV) F glycoprotein, the findings highlight potential benefits of similar vaccines in humans, as no licensed hRSV vaccine is currently ...
A few months after touting its RSV vaccine's effects on younger adults, Pfizer said a sub-study focusing on immunocompromised adults is also positive. The data could offer another boost to ...
In addition to our stabilized RSV F protein, DT-preF, we are currently applying the technology to design and engineer a universal influenza vaccine immunogen. Given the large market and medical need for an RSV vaccine, several groups are pursuing strategies encompassing multiple vaccine modalities (...
S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592–598 (2013). Article ADS CAS PubMed PubMed Central Google Scholar Joyce, M. G. et al. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat...
When administered via an intramuscular prime-intranasal boost (IM-IN) regimen in mice, superior protection was generated against challenge with either RSV A, Influenza A H3N2 or H1N1. These results support further clinical development of a pan influenza & RSV vaccine administered in a prime-pull ...
The present application relates to the field of immunology, in particular, a vaccine composition of respiratory syncytial virus (RSV) surface proteins, Fusion (F) and Glycoprotein (
This added time for effective immunization could allow multiple doses of vaccine to be given to an infant and/or doses to be given later in infancy, when the immune system is more mature but still before the infant's first RSV infection or RSV-caused illness. As used herein, an infant ...